bioAffinity Technologies Inc.
BIAF | NASDAQ
$8.80
+$1.10 (+14.29%)
Sep 22, 2026, 2:18 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 6.16M | 9.36M | 2.53M | 4.8K | n/a | n/a |
Cost of Revenue | 4.73M | 5.98M | 1.74M | 467 | 4.82K | 22.24K |
Gross Profit | 1.43M | 3.38M | 791.62K | 4.34K | -4.82K | -22.24K |
Operating Income | -10.57M | -8.95M | -7.97M | -4.01M | -2.21M | -2.6M |
Interest Income | 23.39K | 17.61K | 122.13K | 46.71K | 424 | n/a |
Pretax Income | -14.87M | -9.03M | -7.92M | -8.15M | -6.32M | -7.27M |
Net Income | -14.91M | -9.04M | -7.94M | -8.15M | -6.33M | -7.27M |
Selling & General & Admin | 9.91M | 9.94M | 6.79M | 2.48M | 1.07M | 972.1K |
Research & Development | 2.09M | 1.78M | 1.73M | 1.52M | 1.14M | 1.61M |
Other Expenses | n/a | 606K | 249.59K | 10.18K | n/a | n/a |
Operating Expenses | 12M | 12.33M | 8.77M | 4.02M | 2.2M | 2.58M |
Interest Expense | 44.37K | 92.48K | 37.13K | 2.53M | 1M | 382.17K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 188.1K | n/a |
Cost & Expenses | 16.73M | 18.32M | 10.51M | 4.02M | 2.21M | 2.6M |
Income Tax Expense | 44.04K | 11.65K | 20.99K | 2.46K | 1.95K | 2.75K |
Shares Outstanding (Basic) | 114.74K | 26.96K | 19.44K | 10K | 5.95K | 16.4K |
Shares Outstanding (Diluted) | 114.74K | 26.96K | 19.44K | 10K | 6.06K | 16.4K |
EPS (Basic) | -129.90 | -337.50 | -409.50 | -814.50 | -1.06K | -445.50 |
EPS (Diluted) | -129.90 | -337.50 | -409.50 | -814.50 | -1.04K | -445.50 |
EBITDA | -14.32M | -8.33M | -7.63M | -5.61M | -5.32M | -6.86M |
EBIT | -14.82M | -8.94M | -7.88M | -5.62M | -5.32M | -6.88M |
Depreciation & Amortization | 504.84K | 605.64K | 249.59K | 10.18K | 4.82K | 22.24K |
Add to Watchlist
Select watchlists to add or remove BIAF